• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

3-arylisoquinolinamine derivative Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5752614

MBS5752614 is an inhibitor targeting 3-arylisoquinolinamine derivative. 3-arylisoquinolinamine derivative is a compound with antitumor activity. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
3-arylisoquinolinamine derivative, Inhibitor
Full Product Name
3-arylisoquinolinamine derivative
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
293.36
Solubility
DMSO: 50mg/mL (170.44mM)
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C18H19N3O
SMILES
NC1=NC(C2=CC=CC(OC)=C2)=CC(C=C3)=C1C=C3N(C)C
CAS Number
1029008-71-6
Target & IC50
breast MDA-MB-231: ic50 21nM
pancreas PANC-1: ic50 19nM
colon HCT 116: ic50 17nM
prostate PC3: ic50 19nM
ovary OVCAR-3: ic50 14nM
melanoma SK-MEL-28: ic50 32nM
kidney Caki-1: ic50 22nM
glioblastoma SNB19: ic50 32nM
In Vitro
3-arylisoquinolinamine derivative has higher antitumor efficacy (69.2% inhibition) than that of the control drug, Paclitaxel (48.8% inhibition) in the inhibition of growth of tumor in an animal model [2].

Product References and Citations for 3-arylisoquinolinamine derivative, inhibitor

Yang SH, et al. Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5277-81.
Yang SH, et al. Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5277-81.
Young Bok Lee, et al. 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents. WO 2008063548 A2.
Young Bok Lee, et al. 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents. WO 2008063548 A2.

Other Notes

Small volumes of 3-arylisoquinolinamine derivative, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000